fda-and-biotech News
Vaccine Stocks Surge After First Fatal Human H5N5 Case in US
Moderna jumps over 6% as investors speculate on pandemic preparedness, but a shift in U.S. funding strategy presents a complex outlook.
Praxis Insiders Unload $7.5M in Stock After 300% Rally
Executive profit-taking follows a massive stock surge driven by positive clinical trial data for the company's essential tremor drug, ulixacaltamide.
Pfizer Surges After FDA Approves Key Bladder Cancer Drug Combo
The approval for PADCEV with Merck’s Keytruda validates Pfizer's $43 billion Seagen acquisition and establishes a new standard of care in a growing oncology market.
Merck Gains FDA Nod for Keytruda Combo in Bladder Cancer
Approval for use with Pfizer/Astellas's Padcev establishes a new standard of care for first-line treatment, bolstering the blockbuster drug's market dominance.
Contineum Plunges Over 30% as MS Drug Misses Trial Goals
The clinical-stage biotech's lead drug candidate, PIPE-307, failed to meet primary and secondary endpoints in a pivotal Phase 2 study, erasing recent gains.
Pfizer Shares Climb Over 3% on Promising mRNA Flu Vaccine Data
Phase 3 trial results show its next-generation vaccine outperforms traditional shots, boosting confidence in the company's post-COVID growth strategy.
SELLAS Director Buys $101K in Stock Amid Share Price Weakness
The open-market purchase by board member Katherine Bach Kalin signals insider confidence as the biotech advances its late-stage cancer therapies.
AnaptysBio Stock Slides as GSK Lawsuit Threatens Jemperli Royalties
Biotech firm and GSK's Tesaro unit file dueling lawsuits over alleged contract breaches, placing a critical cancer drug revenue stream at risk.